Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

  1. Mandy Jongeneelen
  2. Krisztian Kaszas
  3. Daniel Veldman
  4. Jeroen Huizingh
  5. Remko van der Vlugt
  6. Theo Schouten
  7. David Zuijdgeest
  8. Taco Uil
  9. Griet van Roey
  10. Nuria Guimera
  11. Marjon Navis
  12. Rinke Bos
  13. Mathieu le Gars
  14. Jerald Sadoff
  15. Leacky Muchene
  16. Jarek Juraszek
  17. Johannes PM Langedijk
  18. Ronald Vogels
  19. Jerome Custers
  20. Hanneke Schuitemaker
  21. Boerries Brandenburg
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and recently emerging variants with substitutions in the Spike protein have led to growing concerns over increased transmissibility and decreased vaccine coverage due to immune evasion. Here, sera from recipients of a single dose of our Ad26.COV2.S COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants of concern. All tested variants demonstrated susceptibility to Ad26.COV2.S-induced serum neutralization albeit mainly reduced as compared to the B.1 strain. Most pronounced reduction was observed for the B.1.351 (Beta; 3.6-fold) and P.1 (Gamma; 3.4-fold) variants that contain similar mutations in the receptor-binding domain (RBD) while only a 1.6-fold reduction was observed for the widely spreading B.1.617.2 (Delta) variant.

Related articles

Related articles are currently not available for this article.